Editorial

Dolutegravir for second-line treatment: Programmatic implications of new evidence

Ying Zhao, Gary Maartens, Graeme Meintjes
Southern African Journal of HIV Medicine | Vol 23, No 1 | a1428 | DOI: https://doi.org/10.4102/sajhivmed.v23i1.1428 | © 2022 Ying Zhao, Gary Maartens, Graeme Meintjes | This work is licensed under CC Attribution 4.0
Submitted: 06 July 2022 | Published: 05 September 2022

About the author(s)

Ying Zhao, Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Gary Maartens, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; and, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Graeme Meintjes, Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Abstract

No abstract available.

Keywords

antiretroviral therapy; HIV; dolutegravir; second-line

Metrics

Total abstract views: 3357
Total article views: 6267

 

Crossref Citations

1. Dolutegravir resistance in three pregnant and breastfeeding women in South Africa
Ninke Fourie, Kate Rees, Denis Mali, Bridget Mugisa, Cara O’Connor, Natasha Davies
Southern African Journal of HIV Medicine  vol: 24  issue: 1  year: 2023  
doi: 10.4102/sajhivmed.v24i1.1531

2. Outcomes and characteristics of patients on protease inhibitors at a tertiary level antiretroviral clinic
Michele Perks, Denasha L. Reddy, Francois Venter
Southern African Journal of HIV Medicine  vol: 24  issue: 1  year: 2023  
doi: 10.4102/sajhivmed.v24i1.1536

3. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study
Kwabena Asare, Yukteshwar Sookrajh, Johan van der Molen, Thokozani Khubone, Lara Lewis, Richard J Lessells, Kogieleum Naidoo, Phelelani Sosibo, Rosemary van Heerden, Nigel Garrett, Jienchi Dorward
The Lancet Global Health  vol: 12  issue: 2  first page: e282  year: 2024  
doi: 10.1016/S2214-109X(23)00516-8